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decreases in the frequencies of heterozygous (GT), and
T allele of FXIII Val34Leu in UA patients group, com-
pared with the control group assuming a protective role
of FXIII 34Leu allele against unstable angina develop-
ment. The prevalence of other studied polymorphisms;
factor V H1299R (R2), Glycoprotein IIIa Leu33Pro,PAI-1
4G/5G, MTHFR C677T polymorphisms, MTHFR
A1298C, apo B R3500Q and apo E polymorphisms; did
not differ between IHD patients and control subjects.
There was a significant positive association between
FVL and family history of IHD in AMI patients. In addi-
tion, a highest prevalence of Pl A2 in patients <35 years
of age surviving a first AMI, so that age-at-onset of AMI
was significantly affected by PlA2 (<35 years vs. 35–40).
Apo E3/E4 genotype was associated with both high total
Cholesterol (TC) and high TC/HDL ratio in UA group,
while in AMI patients, Apo E3/E4 genotype was associ-
ated with high TC/HDL ratio, and high triglycerides
levels.
Conclusions: This study has identified a positive
association for FV Leiden, Prothrombin G20210A hetero-
zygosity, and ACE (I/D) polymorphism with premature
AMI; a positive association for b-fibrinogen 455-GA poly-
morphism in UA patients; and a negative association
(protective role) for FXIII Val34Leu in UA patients. This
study may open a dooor to promised goals of new thera-
peutics and personalised medicine for premature IHD
based on single nucleotide polymorphism in well defined
groups of high risk patients (<40 years); and their
families.
http://dx.doi:10.1016/j.jsha.2013.03.107
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Background: Fetal heterotopic tachycardia is associ-
ated with a high risk of congestive heart failure, fetal
hydrops and intrauterine death. Transplacental treat-
ment by antiarrhythmic agents can improve prognosis
dramatically.
Objectives: The aim of our study is to review the
management and the outcome of heterotopic tachycardia
in fetal patients treated in our center.
Methods: We reported 24 cases of heterotopic fetal
tachycardia diagnosed and treated mainly with digoxin
and/or amiodarone administered by the transplacental
way.
Results: Twenty four fetal patients were studied,
thirteen with supraventricular tachycardia, eight with
atrial flutter and three with chaotic atrial tachycardia.
Among them, eight fetuses were hydropic. All mothers
were given an antiarrythmic treatment by mouth. There
were three intrauterine deaths. Digoxin monotherapy
converted 6/8 non hydropic fetuses and 0/2 hydropic
fetuses who died. Amiodarone monotherapy converted
4/6 including 2 hydropic fetuses with one intrauterine
death. The association of digoxin and amiodarone con-
verted 7/7 fetuse including 3 hydropic patients. No death
found with this association. Propanolol was used in
monotherapy or associated with digoxin in vain in three
patients with chaotic atrial tachycardia.
Conclusions: Maternal oral antiarrhythmic treat-
ment should be given as soon as the diagnosis of fetal
heterotopic tachycardia is done. Digoxin and amiodarone
seems to be effective. Their association is particularly
indicated in hydropic fetuses.
http://dx.doi:10.1016/j.jsha.2013.03.108
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Introduction: Transcatheter closure of perimembra-
nous ventricular septal defect (PM VSD) is abandoned in
many center and in some became restricted to certain age
and criteria because of the risk of complete heart block
(CHB). The risk of damaging the tricuspid valve (TV) in
the presence of inlet extension is another risk. I am pre-
senting successful closure of such defect using Amplatzer
occluder device for PDA with reasonable follow up per-
iod in Prince Sultan Cardiac Center PSCC.
Method: Through 2011 4 patients underwent trans-
catheter closure of PM VSD with inlet extension, all
patients were consented and procedure were done under
general anesthesia, Transesophageal echocardiography
was done in all, one has 3D assessment Hemodynamics
were assessed pre procedural, A–V loop was applied in
2 patients, ADOI were used in all,heparin and antibiotics
were giving during and 24 h post procedure, 3 patients
were extubated same day and one the following day, all
patients were kept on aspirin for 6 months.
Result: Median age 17 kg, 3 female and 1 male, med-
ian age 7 year, Median ventilatory duration is one day,
Median hospital stay is 2 days, Median Follow up is 16
months, No immediate or early complication or deaths,
normal ECG immediately and during follow up period,
normal Echocardiography with no residual leak during
follow up period.
Conclusion: In selected patients with PM VSD and
inlet extension ADOI device can be used safely and effec-
tively to close the defect with no immediate or early
complications.
http://dx.doi:10.1016/j.jsha.2013.03.109
Early experience on aortic arch surgery at King
Fahd Armed Forced Hospital (KFAFH), Jeddah
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